InflaRx N.V. - Common Stock (IFRX)

Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses.

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. All ordinary shares in the offering are being sold by the Company. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions.

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it intends to develop izicopan, an oral C5a receptor (C5aR) inhibitor with potential best-in-class properties, in AAV, a life-threatening kidney disorder. InflaRx is conducting Phase 2 planning for izicopan in AAV and is evaluating the feasibility of multiple development approaches, including the potential for an expedited path to the commercial market, in an effort to best address the evolving regulatory environment surrounding the currently approved comparator, avacopan.

Synergy CHC Corp. (NASDAQ: SNYR), a leading consumer health and wellness company, announced multiple expansion milestones as its flagship FOCUSfactor® Focus + Energy beverage rollout accelerates across the U.S. and internationally.

The revolutionary blockchain ecosystem from Infinitum, powered by Lusis-global leader in financial systems-sets a new standard in security, resilience, and interoperability, bridging traditional and decentralized finance

ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has launched The InflaRx Commitment Program (Commitment Program). Pursuant to the Commitment Program, the cost of GOHIBIC (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements*, for patients who were administered GOHIBIC in line with its EUA and who died due to COVID-19 in the intensive care unit.

InflaRx N.V. (NASDAQ: IFRX) is one today’s most active stocks by volume. So far today, approximately 60.87M shares of InflaRx N.V. have been exchanged, as compared to an average 30-day volume of 620.81k shares.

JENA, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).